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Objectives: To estimate the cumulative incidence and hospital cost for venous and 
pulmonary thromboembolic events in a real world setting in France. MethOds: We 
conducted a retrospective analysis of the EGB database, a 1/97th random sample of 
the whole National health insurance database records linked to hospitalizations. 
All patients hospitalized in 2010 and 2011 with a diagnosis of deep vein thrombo-
sis (DVT) or pulmonary embolism (PE) were included. Inpatients were identified 
through principal diagnosis of hospitalization stay. Outpatients with a DVT were 
identified by 1) an echo Doppler exam, 2) preceded or followed by a low molecular 
weight heparin or fondaparinux delivery (+/-7 days), and 3) a subsequent Vitamin K 
antagonists delivery (0 to 7 days). Incidences and annual hospital cost of DVT and PE 
were estimated and extrapolated to the overall French population, and cumulative 
proportions of recurrences were calculated. Results: For 2011, the estimated crude 
incidences were 141/100,000 (91,650 patients) for DVT, and 79.4/100,000 for PE (51,610 
patients in France). Mean age of patients was 67.0+/-17.2 years for PE and 64.1+/-17.7 
years for DVT. A majority of patients were females (57% in both groups). After index 
event (PE/DVT), the cumulative proportions of venous thromboembolic recurrences 
were 2.6% at 1 month, 3.7% at 3 months, 5.1% at 6 months and 6.7% at 12 months. 
The cumulative proportions of death after a PE and a DVT first event were 0.2% at 1 
month, 1.1% at 3 months, 2.6% at 6 months and 6.2% at 12 months. Annual hospital 
cost of venous and pulmonary thromboembolic events was estimated at 712 million 
€ (362 million € for DVT and 350 million € for PE). cOnclusiOns: In 2011, around 
143,000 patients suffered from venous and pulmonary thromboembolic events in 
France. Hospitalized events accounted for an important burden in France.
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CognitiVe FunCtion And non-AdherenCe to AntihyPertensiVe 
MediCAtions
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Columbia University, New York, NY, USA
Objectives: Non-adherence to blood pressure medications is common, present 
in 30-50% of patients, and known to be associated with an increased risk for major 
cardiovascular events and increased health care costs. Prior research suggests 
that impaired cognitive function is associated with medication non-adherence. 
Our aim was to determine if easily administered measures of cognitive function 
can be used to identify hypertensive patients at increased risk of medication non-
adherence. MethOds: A convenience sample of 101 primary care patients (n= 101) 
with uncontrolled hypertension was enrolled from two hospital-based clinics in 
ethnically diverse communities of New York City. Patients with overt dementia 
as noted by their primary care doctors were ineligible. Subjects completed three 
brief cognitive tests (≤ 5 minutes to complete each one): Trail Making Test-A, Trail 
Making Test-B, and the Symbol Digit Modalities Test. The primary outcome was 
adherence based on percentage of doses taken as prescribed, measured by a 4-com-
partment electronic pillbox (MedSignals). Multivariable logistic regression was used 
to determine if impaired cognitive function was associated with poor adherence 
after adjusting for age, gender, ethnicity, education, and total blood pressure medi-
cations. Results: Patients who were classified as impaired when screened by 
Trail Making Test-B had a three-fold (OR= 2.91,95% CI, 1.02-8.35) increased likeli-
hood of non-adherence compared with those who were not impaired, adjusting 
for age, education, gender, ethnicity, and number of BP medications (p= . 05). Trail 
Making Test-A and Symbol Digit Modalities Test were non-significant predictors of 
adherence in both adjusted and unadjusted analyses. cOnclusiOns: Trail Making 
Test-B, a measure of executive function, may be a useful screening tool to identify 
patients without overt dementia who are at risk for non-adherence to anti-hyper-
tensive medications. The findings from this study may provide an opportunity to 
identify a tailored approach to medication adherence interventions.
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Objectives: Hyperuricemia is an independent risk factor for gouty arthropathy, 
renal disease, atherosclerosis and cardiovascular diseases (CVD). The objective of 
this study was to explore the relationship between serum uric acid (SUA) levels and 
hospitalization events and assess health care costs. MethOds: A retrospective 
analysis using a large administrative database and a clinical registry containing 
laboratory results was performed. Subjects, aged ≥ 18, were assigned to one of 
the 4 groups based upon the first SUA measurement between October 1, 2010 and 
September 30, 2011: ≤ 6 mg/dl [good-control], > 6 mg/dl and ≤ 7 mg/dl [fair-control], 
> 7 mg/dl and ≤ 8 mg/dl [poor-control], > 8 mg/dl [very-poor-control]. We calculated 
incidence rates to estimate the risk of hyperuricemia-related and CVD hospitaliza-
tions occurred until December, 2012. A Poisson regression model was used to assess 
the relationship between the number of CVD hospitalizations and SUA level. Total 
annual costs included all the pharmacological treatments and the direct costs due 
to hospitalizations and outpatient services. Results: Of 52,822 patients included, 
SUA level was ≤ 6 mg/dl -good-control- for 33,638 (63.7%) patients and > 6 mg/dl 
–suboptimal-control- for 19,184 patients (36,3%), of whom 60,7% with fair-control, 
25,8% poor-control and 13,5% very-poor-control. Compared with good-control group, 
suboptimal-control patients showed an increased risk of hyperuricemia-related hos-
pitalizations (unadjusted rate was 1,02 vs 0,43 per 1000 person-years, p< 0.001) and 
of CVD hospitalizations (unadjusted rate 5,09 vs 3,17 per 100 person-years, p< 0.001; 
adjusted incidence rate ratio 1.22, p< 0.001). Over one year, the mean total cost was: 
€ 2,077.43 in good-control patients; € 2,079.87 in fair-control patients; € 2,296.39 in 
poor-control patients; € 3,295.41 in very-poor-control patients. cOnclusiOns: The 
36,3% of the patients in this study sample were at sub-optimal SUA control (> 6mg/dl). 
This analysis indicates that higher hyperuricemia-related and CVD hospitaliza-
tions as well as total health care costs resulted associated with higher SUA levels.
tified from the Clinical Practice Research Datalink (CPRD). From this cohort, three 
groups of patients were identified and counted for 2010, 2011 & 2012: Group 1 – 
very high-risk T2DM patients with CVD, TC ≥ 4.0 to < 5.0mmol/l and low-density 
lipoprotein cholesterol ≥ 2.0mmol/l despite statin treatment; Group 2 – untreated 
patients, with a TC ≥ 5.0mmol/l who were not prescribed any LLT after ceasing statin 
therapy; Group 3 – patients prescribed atorvastatin, rosuvastatin and/or ezetimibe 
with TC < 5.0mmol/l who previously had TC ≥ 5.0mmol/l. Numbers were extrapolated 
to the population in England. Results: Of the general population in England in 
2012, 8, 200, 699 (15.4%) patients had a TC test recorded, with similar proportions 
in 2010 & 2011 (15.4% and 15.3% respectively). Among the three groups defined in 
this analysis, a total of 305, 261 patients eligible for ezetimibe were not included 
in the 2012 estimates by HSCIC. This represents an 80.0% increase of the original 
estimate of 381, 797 patients using the original HSCIC methodology, corresponding 
to 33, 753, 141, 619, and 129, 889 patients in Groups 1, 2 and 3, respectively. Hence 
a year-on-year increase in the estimated eligible population were observed com-
pared to the original HSCIC estimate; 64.8% increase in 2010 and 75.7% increase in 
2011. cOnclusiOns: A significant and increasing number of high-risk patients 
eligible for ezetimibe were missed in the HSCIC estimates during 2010-2012.
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Objectives: describe the prevalence of venous thromboembolism (VTE), pul-
monary embolism (PE) and deep vein thrombosis (DVT) without PE among all 
hospitalized patients and the percentages of those occurring during the hospital 
stays. MethOds: Statistics are issued from the national PMSI MCO databases which 
are encoded using the CIM10. The codes used for VTE are I801 to I809 for DVT and 
codes I260, I269 for PE... Any stay with a the ICD-10 codes selected regardless of the 
Principal Diagnosis of Medical Unit Summaries and whatever its position (Principal, 
Related or Associated Diagnosis) was considered as a hospital-occurred thrombo-
sis unless it was the Principal Diagnosis of the first Medical Unit Summary of the 
stay. To eliminate outpatient consultations or in day care, stays of < 48 hours were 
excluded. The term of hospital-occurred is preferred to hospital-acquired VTE sug-
gesting a nosocomial origin which can be the case or not. Results: The results bear 
on the 18 683 603 hospital stays in 2010-2011. Out of 100 hospital stays involving VTE, 
for 40.3% VTE was the cause of hospitalization whereas 59.7% can be considered 
to have occurred during hospital-stay. These distributions are of 25.6% and 74.4% 
for DVT respectively 53.8% and 46.2% for PE. The age of patients varies little with 
whether VTE, DVT, and PE were hospital-occurred or not and are similar in men 
and women. The percentage of mortalities of these VTE is high and reaches 6.58% 
and the mortality from VTE, DVT, and PE is multiplied by a factor of 3 to 4 (p< . 0001) 
when hospital-occurred. cOnclusiOns: The high proportion of hospital-occurred 
VTE is an alarming situation that should question the quality of prevention and/or 
its effectiveness. VTE prevention policies must be strengthened in hospitals for the 
sake of patients and health care savings alike.
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Objectives: This study estimated venous thromboembolism (VTE) recurrence 
and associated risk factors in a European population, given limited data in this 
region. MethOds: This retrospective cohort study included data from physicians 
(376 general practitioners and 307 specialists) in France, Spain, Italy, and Germany, 
who completed case report forms (2,184 patient records) for the next 3-4 patients 
seen in consultation for any reason who had an initial VTE event 3 to 24 months 
prior (i.e., patients surviving 90 days since initial VTE). All Anderson & Spencer 
individual risk factors (plus gender, bleeding, and initial VTE type, but excluding 
previous VTE and bed rest > 3 days) were entered into a Cox proportional hazard 
model accounting for censored data and predicting VTE recurrence. Backward step-
wise regression was used to select a reduced final model. Results: Patients’ mean 
age was 61.3 years (SD= 14.3) and 47.4% were female. Of 2,184 patients, 379 devel-
oped recurrent VTE over 1,298 person-years of follow-up. The final model included: 
age= 40+ (91.6%) vs. 18-39 years, varicose veins (26.4%), history of heart failure (5.9%), 
congestive respiratory failure (1.3%), arthroscopic knee surgery (2.2%), central 
venous line (0.9%), chemotherapy (6.1%), and orthopedic (3.1%) surgery. Significant, 
independent predictors of recurrence were: varicose veins (hazard ratio [HR]: 1.4; 
95% confidence interval [CI] 1.1-1.8), central venous line (HR: 3.2; CI 1.5-6.8), con-
gestive respiratory failure (HR: 2.4; CI 1.2-4.6), and heart failure (HR: 1.5; CI 1.1-2.2). 
Other factors, including age= 40+, knee surgery, chemotherapy, orthopedic surgery, 
and type of VTE (e.g., deep vein thrombosis vs. pulmonary embolism) did not exhibit 
significant associations with recurrence of VTE. cOnclusiOns: VTE recurrence is 
high in this European population and associated with several independent risk fac-
tors. Targeted anticoagulant treatment post-initial VTE plus longer term prevention 
of recurrence are needed, including attention to risk factors that help differentiate 
patients more likely to experience recurrence.
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diseAse: systeMAtiC literAture reView And MetA-AnAlysis
Thakker D., Nair S.R., Shukla H, Shaikh J.S.
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Objectives: Statins are widely used for the primary and secondary prevention 
of cardiovascular diseases (CVDs). Studies have shown that statins may induce 
diabetes in non-diabetic CVD patients, as class effect. This systematic literature 
review aims to evaluate the risk of developing diabetes in CVD patients receiving 
statins. MethOds: Randomized controlled trials (RCTs), which used any statin as 
an intervention for non-diabetic CVD patients, were identified from August 2010 
to June 2014 in databases such as, Embase, PubMed, and Cochrane. The timeframe 
of the searches was selected post the study conducted by Mills et al. in 2011. This 
review will also include relevant studies from the Mills et al. study until August 2010. 
Two researchers will independently review studies as per the Cochrane method-
ology for systematic reviews. The primary outcome is the incidence of diabetes. 
Subgroup analyses will also be performed to assess whether statin type, age, eth-
nicity or patient groups contribute to the intensity of the risk of developing dia-
betes. Results: In total, 5238 potentially relevant studies were retrieved from the 
databases and are being screened for inclusion in the review. The data extraction 
and analyses (both qualitative and quantitative) are being performed and the full 
results will be presented in the poster. cOnclusiOns: This systematic literature 
review is an update of the findings of a previous study and will hopefully throw 
more light on the association between statin use and the risk of diabetes in CVD 
patients, with special emphasis on subgroups.
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A retrosPeCtiVe study oF MortAlity in risk PAtients with high dose 
stAtin usAge And no stAtin usAge
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Objectives: The aim of this retrospective cohort study was to calculate hazard 
rates of CV/non-CV related death in risk patients stratified by statin dose and to 
generate data for health-economic analyses. MethOds: Anonymous retrospective 
electronic medical records were extracted from a 10% sample of the Swedish popula-
tion > 18 years in primary care and merged with hospital records, prescribed drugs, 
and death data by National Board of Health and Welfare. Cohorts were defined as 
diabetic (DM), Clinically-evident CardioVascular Disease (CeCVD), Acute Coronary 
Syndrome (ACS), Heart Failure (HF) and Ischemic Stroke (IS) patients. CV/non-CV 
related death was investigated. The population was divided into high dose statin 
users (> 40 mg simvastatin or equivalent) and non-statin users. Royston Parmar (RP) 
spline analysis was used to calculate hazard rates of both outcomes in each cohort 
to enable a smooth hazard function with good fit to data compared to ordinary Cox 
regression. Initial AIC-based optimization demonstrated that modeling of the log 
cumulative odds as a spline function of log time and three nodes gave the best fit. 
Crude rates were calculated for each cohort and event, and hazard rates adjusted 
for gender, diabetes, LDL (where applicable) and age were calculated. Results: 
The total database consisted of 1.3 million patients; there were 55,778 DM, 47,581 
CeCVD, 49,857 ACS, 82,835 HF and 38,949 IS patients. High dose statin users showed 
after initial decrease a constant/marginally increasing hazard rate, whereas the no 
statin group after initial decrease had a strong increase in hazard rate versus time. 
The overall hazard rate was always higher for the no statin group. Independent of 
statin status diabetics and males demonstrated an at least numeric elevated hazard 
rate. cOnclusiOns: RP splines could be used to generate hazard rate functions 
for cost-effectiveness models. The death rate was lower in patients with high dose 
statin usage.
CArdioVAsCulAr disorders – Cost studies
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Objectives: Varenicline is indicated for smoking cessation. Around 60.000 peo-
ple die every year in Spain because of tobacco related diseases, particularly car-
diovascular diseases (CVD), chronic obstructive pulmonary disease (COPD) and 
type-2 diabetes mellitus (t2DM). At present, varenicline is not reimbursed in the 
Spanish National Health System (NHS). The objective was to estimate the budgetary 
impact (BI) for the NHS of the reimbursement of varenicline in smoking cessation 
in patients with CVD, COPD or t2DM. MethOds: BI was estimated comparing the 
actual not-reimbursed scenario versus a reimbursed scenario using the Spanish 
NHS perspective. A hybrid BI model was designed using epidemiological data to 
estimate size of populations and a Markov modelling simulating until four quit-
ting attempts to estimate smoking cessation rates with varenicline during a 5-year 
horizon. Costs of cessation attempts were considered in the reimbursement sce-
nario only, and included varenicline, medical visits and counselling. Effectiveness 
of varenicline was expressed as one year of abstinence rate following a 12-weeks 
course of standard doses, and were derived from clinical trials. Cost savings due to 
smoking cessation were extracted from local published cost-of-illness studies in 
such populations. Results showed incremental cost-savings of reimbursed versus 
not reimbursed scenario. Univariate sensitivity analysis was also applied. Results: 
Five-years cumulated cessation attempts increased from 140,795 in the not-reim-
bursed to 354,631 in the reimbursed scenario, yielding to 52,127 extra subjects 
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Objectives: Evidence suggests an association between dental disease and car-
diovascular disease (CVD). C-reactive protein (CRP), an inflammatory marker, has 
been implicated as a risk factor for CVD, and dental disease can affect CRP levels. 
Our study examined the relationship between the timing and nature of dental 
visits and CRP. MethOds: Using data from the US-based 1999-2000, 2001-2002, 
and 2003-2004 National Health and Nutrition Examination Surveys, we examined 
the relationship between time since and reason for most recent dental visit and 
CRP among adults ≥ 20 years old. Participants were excluded if they were pregnant 
at the time of the survey, did not take part in the examination component of the 
survey, or were missing covariates for a logistic regression model: age, sex, race, 
BMI, HbA1c, WBC count, CRP measure, time since and reason for last dental visit, 
smoking status, cholesterol-lowering medication use, and history of asthma, cancer, 
rheumatoid arthritis, chronic bronchitis, or recent illness. A dichotomous elevated 
CRP measure was used, defined as CRP > 0.30 mg/dL. Time since last dental visit 
was categorized as < 6 months, 6 months to < 1 year, 1 year to < 2 years, and 2+ 
years ago; respondents who reported never visiting a dentist were placed in the 
2+ years category. Results: A greater proportion of the normal (≤ 0.30 mg/dL) CRP 
group last visited a dentist < 6 months ago (P= 0.0460), and last visited the dentist 
for a “preventive” visit (P< 0.0001), while a greater proportion of the elevated CRP 
group last visited the dentist for a “symptom-driven” visit (P< 0.0001). Regression 
model results demonstrated that preventive visits are associated with a reduced 
likelihood of elevated CRP (OR= 0.722; P= 0.0120), regardless of the time since last 
visit. cOnclusiOns: Given the apparent association between risk of elevated CRP 
and reason for the last dental visit, medical and dental providers should consider 
interventions specifically around appropriate dental care.
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Objectives: A systematic literature review of longitudinal studies across a broad 
range of both general and disease specific populations was performed to understand 
characteristics of patients with type 2 diabetes (T2D) with risk factors for cardiovas-
cular (CV) events and whether the magnitude of CV risk varies across different T2D 
populations. MethOds: MeSH term based literature searches were performed in 
the PubMed, EMBASE and Cochrane Library databases. For inclusion, studies (in any 
disease area) were required to have a minimum of 1,000 T2D patients and minimum 
5 years follow up. After 2 rounds of review a total of 52 articles and 2 meta-analyses 
were included. Results: Twenty nine articles were described as prospective studies; 
13 articles were from Europe, 20 from Asia Pacific, 13 from North America, 2 from the 
Middle East and 4 were multinational. Six articles were sourced from general or non-
diabetes specific data and 46 articles were based on diabetes studies. Several publica-
tions were from large scale diabetes registries (e.g. Hong Kong Diabetes Registry [n= 6] 
and the Swedish National Diabetes Register [n= 4]). The review also identified several 
post-hoc analyses from clinical trials and large scale retrospective observational/
database analyses. Risk factors investigated included well characterized markers in 
T2D patients (e.g. HbA1c, blood pressure, lipids, proteinuria [n= 20]), less well char-
acterized factors including dietary components (n= 7), biochemical measures (e.g. 
serum uric acid, fibrinogen; n= 6), depression (n= 6) and poorly characterized risk 
factors including oral health (n= 1), erectile dysfunction (n= 1) and presence of H. pylori 
(n= 1). cOnclusiOns: Analysis of the literature showed that in addition to traditional 
risk markers, factors such as depression, erectile dysfunction, poor oral health are also 
independent risk factors for CV disease. These factors should be taken into account 
when estimating the CV risk profile for patients with T2D.
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Objectives: Warfarin use in atrial fibrillation has been established for preventing 
occurrence of stroke in patients with atrial fibrillation. However, safety and clinical 
monitoring of warfarin use is crucial due to its risk of bleeding complications. This 
study aims to compare and establish relation of time in therapeutic range (TTR) of 
warfarin in patients with atrial fibrillation in the first 6 months and 6 month thereaf-
ter of anticoagulation therapy. MethOds: This is a retrospective study carried out at 
a tertiary-care hospital with anticoagulation clinic in the state of Selangor, Malaysia. 
Data collected included patients’ demographics, co-morbidities, and international 
normalized ratio (INR). TTR were determined using Rosendaal method based on 
records found in database (INR Desk 4.0 system) and patients’ hemorrhage events 
were also recorded. Samples of the study were patient who started warfarin from 
January 2009 until March 2013. Results: A total of 167 patients with atrial fibrilla-
tion were enrolled and only 6% (n= 10) achieved TTR of more than 75% for the first 
6 months of warfarin use as compared to 16.8% (n= 28) of TTR more than 75% 6 
months thereafter. As for bleeding incidences, 29% (n= 45) of patients in the group 
of TTR less than 75% in the first 6 months had bleeding complications as compared 
to 18.7% (n= 26) in patients of TTR less than 75% 6 months after. cOnclusiOns: 
A more regular follow up is necessary during the first 6 months of new warfarin 
users as they tend to be out of the TTR and have a higher bleeding risk.
